Reference : Validation of OSIRIS, a prescreening tool for the identification of women with an inc...
Scientific journals : Article
Human health sciences : General & internal medicine
Validation of OSIRIS, a prescreening tool for the identification of women with an increased risk of osteoporosis.
REGINSTER, Jean-Yves mailto [Centre Hospitalier Universitaire de Liège - CHU > > Médecine de l'appareil locomoteur]
Ben Sedrine, Wafa mailto [Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé]
Viethel, P. [> > > >]
Micheletti, M. C. [> > > >]
Chevallier, T. [> > > >]
Audran, M. [> > > >]
Gynecological Endocrinology
Taylor & Francis
Yes (verified by ORBi)
United Kingdom
[en] Absorptiometry, Photon ; Adult ; Aged ; Bone Density ; Case-Control Studies ; Female ; Humans ; Mass Screening/methods ; Middle Aged ; Osteoporosis, Postmenopausal/diagnosis/epidemiology/etiology/pathology/radiography ; Predictive Value of Tests ; Prospective Studies ; Sensitivity and Specificity ; Severity of Illness Index
[en] According to the recent recommendations of the European Community and the World Health Organization, identification of risk factors for fracture or low bone mineral density (BMD) should help health professionals to make a better use of bone densitometry. This includes helping patients to modify their behaviour and act on modifiable risk factors (correction of low calcium intake and vitamin D deficiencies, etc.) and also to provide evidence-based guidance for starting a treatment when necessary. In this context, we previously developed a clinical scoring index, OSIRIS (OSteoporosis Index of RISk), for classifying women into three categories of risk of osteoporosis. In order to evaluate the discriminatory performance of OSIRIS, we performed the present prospective study in a sample of 889 postmenopausal women from France. The osteoporosis risk depends on the OSIRIS category. Thus, 62% of women in the 'high-risk' category (OSIRIS < or = -3) were osteoporotic, compared to 34% of women in the 'intermediate-risk' category (OSIRIS ranged between -3 and +1) and only 16.8% of women in the 'low-risk' category (score OSIRIS > 1). These results might contribute to the development of more efficient screening strategies for osteoporosis. The patients in the low-risk category do not require immediate BMD testing; women with 'intermediate risk' have to be carefully followed by their doctor with BMD testing decided on a case-by-case basis; for those within the high-risk category, treatment may be initiated immediately and BMD testing performed either to assess the efficacy of the treatment or to increase the long-term compliance of the patient. In conclusion, for clinical practice, a user-friendly tool has been developed. This tool, called OSIRIS, as far as a simple rule allows, identifies the level of osteoporosis risk in women.

File(s) associated to this reference

Fulltext file(s):

Restricted access
Validation of OSIRIS.pdfPublisher postprint499.31 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.